Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Once-Weekly Semaglutide in Adults with Overweight or Obesity
John Wilding, Rachel L. Batterham, Salvatore Calanna, et al.
New England Journal of Medicine (2021) Vol. 384, Iss. 11, pp. 989-1002
Open Access | Times Cited: 2540

Showing 1-25 of 2540 citing articles:

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Connie W. Tsao, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2023) Vol. 147, Iss. 8
Open Access | Times Cited: 4195
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 3, pp. 205-216
Open Access | Times Cited: 1714
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1153
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1137
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Seth S. Martin, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2024) Vol. 149, Iss. 8
Open Access | Times Cited: 882
European Society of Cardiology: cardiovascular disease statistics 2021
Adam Timmis, Panos Vardas, Nick Townsend, et al.
European Heart Journal (2021) Vol. 43, Iss. 8, pp. 716-799
Open Access | Times Cited: 770
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie J. Davies, Louise Færch, Ole K. Jeppesen, et al.
The Lancet (2021) Vol. 397, Iss. 10278, pp. 971-984
Closed Access | Times Cited: 757
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 688
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 670
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 651
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Mikhail Kosiborod, Steen Z. Abildstrøm, Barry A. Borlaug, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 12, pp. 1069-1084
Open Access | Times Cited: 640
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
Thomas A. Wadden, Timothy S. Bailey, Liana K. Billings, et al.
JAMA (2021) Vol. 325, Iss. 14, pp. 1403-1403
Open Access | Times Cited: 623
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
Domenica Rubino, Frank L. Greenway, Usman Khalid, et al.
JAMA (2022) Vol. 327, Iss. 2, pp. 138-138
Open Access | Times Cited: 580
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Peng Kong, Ziyang Cui, Xiao-Fu Huang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 577
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 557
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
Rachael A. Evans, Hamish McAuley, Ewen M. Harrison, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 11, pp. 1275-1287
Open Access | Times Cited: 548
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 514-526
Closed Access | Times Cited: 468
The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
R. I. G. Holt, J. Hans DeVries, Amy Hess-Fischl, et al.
Diabetes Care (2021) Vol. 44, Iss. 11, pp. 2589-2625
Open Access | Times Cited: 433
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
John Wilding, Rachel L. Batterham, Melanie J. Davies, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 8, pp. 1553-1564
Open Access | Times Cited: 425
Findings from the Global Burden of Disease Study 2021
Christopher J L Murray
The Lancet (2024) Vol. 403, Iss. 10440, pp. 2259-2262
Closed Access | Times Cited: 416
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W. Timothy Garvey, Rachel L. Batterham, Meena Bhatta, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2083-2091
Open Access | Times Cited: 415
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 383
Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association
P. Barton Duell, Francine K. Welty, Michael Miller, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2022) Vol. 42, Iss. 6
Open Access | Times Cited: 383
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Joshua J. Joseph, Prakash Deedwania, Tushar Acharya, et al.
Circulation (2022) Vol. 145, Iss. 9
Open Access | Times Cited: 376
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Ildiko Lingvay, Priya Sumithran, Ricardo V. Cohen, et al.
The Lancet (2021) Vol. 399, Iss. 10322, pp. 394-405
Closed Access | Times Cited: 368
Page 1 - Next Page

Scroll to top